Zobrazeno 1 - 10
of 140
pro vyhledávání: '"David A Margolin"'
Autor:
Nicola L. Brice, Mark Carlton, David H. Margolin, Martin Bexon, Kim L. Matthews, Lee A. Dawson, Aaron L. Ellenbogen, C. Warren Olanow, Jordan Dubow, Karl Kieburtz
Publikováno v:
EClinicalMedicine, Vol 77, Iss , Pp 102882- (2024)
Summary: Background: CVN424 is a GPR6 inverse agonist that provides selective pharmacological control of the indirect striatopallidal pathway. We assessed the safety and efficacy of CVN424 as an adjunctive treatment to levodopa for reducing OFF-time
Externí odkaz:
https://doaj.org/article/03ffbbb6c9d240da9bd6c36037040312
Autor:
Michael J Ripple, Amanda Parker Struckhoff, Jimena Trillo-Tinoco, Li Li, David A Margolin, Robin McGoey, Luis Del Valle
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106257 (2014)
During the last decade, mounting evidence has implicated the human neurotropic virus JC virus in the pathology of colon cancer. However, the mechanisms of JC virus-mediated oncogenesis are still not fully determined. One candidate to mediate these ef
Externí odkaz:
https://doaj.org/article/a4a4c4bfbc42477786daeba81330622e
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1
Externí odkaz:
https://doaj.org/article/0fa2ae77784345bda11b4afff0c00fe1
Autor:
Daniel C. Javitt, Marlene Carlson, David H. Margolin, Nicola Brice, Anna Beloborodova, Heloise M. De Baun, Joshua T. Kantrowitz, Pejman Sehatpour, Mark Carlton
Publikováno v:
Neuropsychopharmacology
Serotonin type-3 receptor (5-HT(3)R) antagonists show potential as a treatment for cognitive deficits in schizophrenia. CVN058, a brain-penetrant, potent and selective 5-HT(3)R antagonist, shows efficacy in rodent models of cognition and was well-tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a447b4e2e4518afc7b32fb11eba5e4
https://doi.org/10.1038/s41386-021-01170-8
https://doi.org/10.1038/s41386-021-01170-8
Publikováno v:
Surgical Endoscopy. 36:1284-1292
Colonoscopy remains the gold standard for screening and surveillance of colorectal neoplasms, and is associated with a lower risk of colorectal cancer (CRC)-related mortality. The current interval surveillance recommendations in patients with previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1de814e08b798d54d8a03bcf2080874a
https://doi.org/10.1007/s00464-021-08403-3
https://doi.org/10.1007/s00464-021-08403-3
Publikováno v:
The American Surgeon. 88:74-82
Background Clostridium difficile infection (CDI) is now the most common cause of healthcare-associated infections, with increasing prevalence, severity, and mortality of nosocomial and community-acquired CDI which makes up approximately one third of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d05438e7b45338ec4a758f1804dc9a4
https://doi.org/10.1177/0003134820973720
https://doi.org/10.1177/0003134820973720
Modified Frailty Index Predicts Postoperative Outcomes in Patients Undergoing Radical Pelvic Surgery
Autor:
Dominique J. Monlezun, Shannon L. McChesney, Heather J. Green, David A. Margolin, Daniel J. Canter
Publikováno v:
The American Surgeon. 86:95-103
Patients undergoing radical pelvic surgery such as proctectomy or radical cystectomy are at risk of experiencing a variety of complications. Frailty renders patients vulnerable to adverse events. We hypothesize that frailty measured preoperatively us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::863a01e79af11966f6fb0b0c559eb7db
https://doi.org/10.1177/000313482008600222
https://doi.org/10.1177/000313482008600222
Autor:
Colin M. Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, Bart Van Wijmeersch, Sven G. Meuth, David H. Margolin, Elizabeth M. Poole, Darren P. Baker, Peter A. Senior
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9:205521732211427
Background Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event. Objective Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b8f13421e3ddd1a0807f2fb37d03bd0
https://doi.org/10.1177/20552173221142741
https://doi.org/10.1177/20552173221142741
Autor:
H. David Vargas, David A. Margolin
Publikováno v:
The ASCRS Textbook of Colon and Rectal Surgery ISBN: 9783030660482
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c136fedd2471b484a944a2069e993a7
https://doi.org/10.1007/978-3-030-66049-9_9
https://doi.org/10.1007/978-3-030-66049-9_9
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 381(1)
CVN424 is a novel small molecule and first-in-class candidate therapeutic to selectively modulate GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b715384157c158490578340a3b61b97
https://pubmed.ncbi.nlm.nih.gov/35110393
https://pubmed.ncbi.nlm.nih.gov/35110393